Research programme: small molecule inhibitors - Galapagos
Latest Information Update: 28 Feb 2024
At a glance
- Originator Fibrocor Therapeutics
- Developer Fibrocor Therapeutics; Galapagos NV
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fibrosis; Idiopathic pulmonary fibrosis